Selective Serotonin Reuptake Inhibitor (SSRI)

DRUG4 trials

Sponsors

Pamlab, Inc., The Cleveland Clinic, Janssen Research & Development, LLC, Khyber Medical University Peshawar

Conditions

Bipolar DisorderDepressive Disorder, MajorMajor DepressionMajor Depressive DisorderPost-Traumatic Stress Disorder (PTSD)

Phase 2

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

CompletedNCT03321526

Janssen Research & Development, LLCDepressive Disorder, Major

Start: 2017-12-12End: 2019-06-27Updated: 2025-04-29

Phase 3

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

RecruitingNCT07703722

Khyber Medical University PeshawarMajor Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)

Start: 2026-04-01End: 2027-11-22Target: 60Updated: 2026-07-14

Phase 4

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

CompletedNCT01811147

The Cleveland ClinicBipolar Disorder, Major Depression

Start: 2011-11-30End: 2018-06-30Updated: 2019-12-02

Unknown Phase

Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis

CompletedNCT01001559

Pamlab, Inc.Major Depressive Disorder

Start: 2009-08-31End: 2011-06-30Updated: 2013-12-19

Related Papers

Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study.

2026-03-09

Sub-threshold bipolar disorder in medication-free young subjects with major depression: Clinical characteristics and antidepressant treatment response.

2018-12-0814 citations